Enjoy complimentary customisation on priority with our Enterprise License!
The PD-1 and PD-L1 inhibitors market share is expected to increase by USD 29.97 billion from 2020 to 2025, and the market's growth momentum will accelerate at a CAGR of 19.11%.
This PD-1 and PD-L1 inhibitors market research report provides valuable insights on the post COVID-19 impact on the market, which will help companies evaluate their business approaches. Furthermore, this report extensively covers PD-1 and PD-L1 inhibitors market segmentation by application (solid tumors and blood-related tumors) and geography (North America, Europe, Asia, and ROW). The PD-1 and PD-L1 inhibitors market report also offers information on several market vendors, including Agenus Inc., Amgen Inc., AnaptysBio Inc., AstraZeneca Plc, BeiGene Ltd., Bristol-Myers Squibb Co., Checkpoint Therapeutics Inc., F. Hoffmann-La Roche Ltd., Merck and Co. Inc., and Pfizer Inc. among others.
Download the Free Report Sample to Unlock the PD-1 and PD-L1 Inhibitors Market Size for the Forecast Period and Other Important Statistics
The reduction in cancer mortality rate is notably driving the PD-1 and PD-L1 inhibitors market growth, although factors such as the availability of alternative therapies may impede market growth. Our research analysts have studied the historical data and deduced the key market drivers and the COVID-19 pandemic impact on the PD-1 and PD-L1 inhibitors industry. The holistic analysis of the drivers will help in deducing end goals and refining marketing strategies to gain a competitive edge.
Key PD-1 and PD-L1 Inhibitors Market Driver
The lack of approved therapies for cancer in the past led to a high mortality rate. However, the market has witnessed a significant decrease in mortality rate owing to the increasing approvals of novel cancer therapies in recent years. While underdeveloped economies such as Niger continue to have high mortality rates, developed countries such as the US, the UK, and Canada have witnessed a significant decrease. The reduction in the mortality rate of cancer is largely due to the availability of novel drugs, including PD-1 and PD-L1 inhibitors. This proven efficacy of the cancer drugs leads to a high patient adherence ratio, thereby driving the market growth. The reducing mortality rates of cancer and the increasing adoption rates of PD-1 and PD-L1 inhibitors are encouraging vendors in the market to spend heavily on research and development (R&D) of novel drugs, which is expected to add significant value to the PD-1 and PD-L1 inhibitors market during the forecast period.
Key PD-1 and PD-L1 Inhibitors Market Challenge
Despite the proven efficacy of PD-1 and PD-L1 inhibitors in the treatment of various types of solid tumors and blood-related tumors, the market faces a heavy threat from the presence of alternative therapies. The increasing prevalence of cancer has resulted in an urgent need for the development of more advanced therapies to treat these indications. As a result, various vendors have started developing therapies for inhibiting PARP and HER-2. These therapies are called targeted anti-cancer therapies, in which the drug works on inhibiting the growth of the cancer-causing cell in the body. There are multiple targeted therapies approved for the treatment of various types of cancer. The global pharmaceutical market has also witnessed the advent of regenerative therapies such as CAR T-cell therapy and gene therapy for the treatment of cancer. The curative nature of regenerative therapies poses a huge threat to the global PD-1 and PD-L1 inhibitors market, and the expected approval of these therapies during the forecast period is expected to increase the threat, leading to less preference for PD-1 and PD-L1 inhibitors.
This PD-1 and PD-L1 market analysis report also provides detailed information on other upcoming trends and challenges that will have a far-reaching effect on the market growth. The actionable insights on the trends and challenges will help companies evaluate and develop growth strategies for 2021-2025.
The parent market, the global pharmaceuticals market, covers products and companies engaged in the R&D or production of generic drugs, non-generic drugs, and veterinary drugs. Technavio calculates the global healthcare market size based on the combined revenue generated by manufacturers/providers of equipment, supplies, pharmaceuticals, biotechnology, and life sciences tools and services.
The report analyzes the market's competitive landscape and offers information on several market vendors, including:
This statistical study of the PD-1 and PD-L1 inhibitors market encompasses successful business strategies deployed by the key vendors. The PD-1 and PD-L1 inhibitors market is fragmented and the vendors are entering into strategic alliances to compete in the market.
To make the most of the opportunities and recover from post COVID-19 impact, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.
The PD-1 and PD-L1 market forecast report offers in-depth insights into key vendor profiles. The profiles include information on the production, sustainability, and prospects of the leading companies.
For more insights on the market share of various regions Request for a FREE sample now!
51% of the market's growth will originate from North America during the forecast period. The US and Canada are the key markets for PD-1 and PD-L1 inhibitors in North America. However, the market growth rate in this region will be slower than the growth of the market in Asia.
This market research report entails detailed information on the competitive intelligence, marketing gaps, and regional opportunities in store for vendors, which will assist in creating efficient business plans.
To gain further insights on the market contribution of various segments Request for a FREE sample
The PD-1 and PD-L1 inhibitors market share growth by the solid tumors segment will be significant during the forecast period. The global PD-1 and PD-L1 inhibitors market has witnessed a significant increase in the approval of drugs for the treatment of various solid tumors in the last four years. This is primarily due to the high efficacy of PD-1 and PD-L1 inhibitors in blocking the cancer cells pathway and helping the T-cells to fight against the cancer-causing cells. The recent approval of IMFINZI, developed by AstraZeneca, for the treatment of urogenital cancer is expected to contribute heavily to the growth of the solid tumors segment.
This report provides an accurate prediction of the contribution of all the segments to the growth of the PD-1 and PD-L1 inhibitors market size and actionable market insights on post COVID-19 impact on each segment.
PD-1 and PD-L1 Inhibitors Market Scope |
|
Report Coverage |
Details |
Page number |
120 |
Base year |
2020 |
Forecast period |
2021-2025 |
Growth momentum & CAGR |
Accelerate at a CAGR of 19.11% |
Market growth 2021-2025 |
$ 29.97 billion |
Market structure |
Fragmented |
YoY growth (%) |
18.40 |
Regional analysis |
North America, Europe, Asia, and ROW |
Performing market contribution |
North America at 51% |
Key consumer countries |
US, Germany, UK, Canada, and China |
Competitive landscape |
Leading companies, Competitive strategies, Consumer engagement scope |
Key companies profiled |
Agenus Inc., Amgen Inc., AnaptysBio Inc., AstraZeneca Plc, BeiGene Ltd., Bristol-Myers Squibb Co., Checkpoint Therapeutics Inc., F. Hoffmann-La Roche Ltd., Merck and Co. Inc., and Pfizer Inc. |
Market dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for the forecast period |
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
We can help! Our analysts can customize this report to meet your requirements. Get in touch
Executive Summary
Market Landscape
Market Sizing
Five Forces Analysis
Market Segmentation by Application
Customer landscape
Geographic Landscape
Vendor Landscape
Vendor Analysis
Appendix
Get the report (PDF) sent to your email within minutes.
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.